Allogeneic murine melanoma cell vaccine

Bc, Knight; Be, Souberbielle; Gp, Rizzardi; Se, Ball; Ag, Dalgleish

doi:10.1097/00008390-199608000-00004

Cited by 40 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the fact that many allogenic cell-based vaccines are derived from cancer cell lines of the same species and type, they may not be able to detect tumor antigens that are unique to the individual patient [ 64 ]. Despite this drawback, many studies have shown increased immunogenicity in prostate cancer and aggressive melanomas [ 65 , 66 ].…”

Section: Cancer Vaccinesmentioning

confidence: 99%

Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Verma,

Pawar,

Srivastava

et al. 2023

Vaccines

View full text Add to dashboard Cite

Therapeutic vaccines are a promising alternative for active immunotherapy for different types of cancers. Therapeutic cancer vaccines aim to prevent immune system responses that are not targeted at the tumors only, but also boost the anti-tumor immunity and promote regression or eradication of the malignancy without, or with minimal, adverse events. Clinical trial data have pushed the development of cancer vaccines forward, and the US Food and Drug Administration authorized the first therapeutic cancer vaccine. In the present review, we discuss the various types of cancer vaccines and different approaches for the development of therapeutic cancer vaccines, along with the current state of knowledge and future prospects. We also discuss how tumor-induced immune suppression limits the effectiveness of therapeutic vaccinations, and strategies to overcome this barrier to design efficacious, long-lasting anti-tumor immune responses in the generation of vaccines.

show abstract

Section: Cancer Vaccinesmentioning

confidence: 99%

Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Verma,

Pawar,

Srivastava

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

Overview of Cancer Vaccines

Copier

Dalgleish

2009

Tumor‐Associated Antigens

View full text Add to dashboard Cite

Sub‐population analysis of human cancer vaccine cells—ultra scale‐down characterization of response to shear

McCoy

Ward

Hoare

2010

Biotech & Bioengineering

View full text Add to dashboard Cite

The allogeneic whole cell therapy field presents a novel challenge for cell line selection. Large numbers of candidates will he screened for desirable traits including cell growth rates and maintenance of critical product attributes. Screening cell lines for susceptibility to large scale processing conditions has become of increasing importance; innovators do not wish to face the quandary of clinically efficacious cell lines that show poor manufacturability. We have previously described an ultra scale-down method for assessing the impact of the hydrodynamic environment on human cells (McCoy et al., 2009). This body of work describes the validation of this experimental approach using a second, clinically tested, human prostate cancer cell line and describes an additional level of sub-population characterisation. The small-scale conditions set were similar to those expected in downstream process, formulation and vial filling operations with maximum shear rates ranging from 30 x 10(3) to 90 x 10(3) s(-1)(equivalent maximum power dissipation rates of 1.5 x 10(3) to 14 x 10(3) W kg(-1)). Changes to critical cell quality attributes such as membrane integrity retention, cell surface marker staining levels (CD9, CD59, CD147) and cell surface marker density is described. Evaluation of two sub-populations which are formed in response to shear showed distinct staining profiles. Identification of these phenotypically distinct populations, derived in response to the same hydrodynamic environment, poses an interesting bio-processing challenge with regards to both maintenance of product quality, but also highlights the potential benefit of process manipulation through shear-rate intervention with regards to product efficacy.

show abstract

Allogeneic murine melanoma cell vaccine

Cited by 40 publications

References 0 publications

Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Overview of Cancer Vaccines

Sub‐population analysis of human cancer vaccine cells—ultra scale‐down characterization of response to shear

Contact Info

Product

Resources

About